Cancer is a prevalent non communicable disease (NCD) and a leading cause of global mortality. Combining chemotherapy with radiation therapy is essential for improving loco regional control and survival rates. Platinum compounds, taxanes, fluoropyrimidines, and other agents are commonly used alongside radiotherapy. However, electrolyte imbalances frequently occur in cancer patients undergoing platinum based chemotherapy and radiation therapy. This prospective observational study aimed to evaluate the incidence of various electrolyte imbalances associated with cisplatin based chemoradiotherapy in diverse cancer patients. The study was conducted at the Department of Radiation Oncology, Sri Venkateswara Institute of Medical Sciences in Tirupati, Andhra Pradesh, India. Sixty patients receiving cisplatin based concurrent chemoradiotherapy were included. Demographic information, including age, gender, and laboratory investigations of serum sodium, potassium, calcium, and magnesium levels, were collected from patient records. The incidence of electrolyte abnormalities was found to be higher during the third cycle of treatment. Moreover, electrolyte imbalances were more prevalent during the delayed phase compared to the acute phase of cisplatin based chemotherapy. This study highlights the association between platinum based chemoradiotherapy and various electrolyte imbalances, including hyponatremia, hypokalemia, hypocalcemia, and hypomagnesemia, in patients with cervical and head and neck carcinomas.